Anika Therapeutics, Inc.
Medical Devices & Tech
160 New Boston Street
Woburn, MA 01801 USA
phone: (781) 932-6616
fax: (781) 935-4120
Symbol ANIK
Exchange Nasdaq
Founded 1993
Employees 62
www.anikatherapeutics.com
Research Sector Medical Devices & Tech
Summary Description
Therapeutic devices designed to repair, protect and heal bone, cartilage and soft tissue.
Management
Charles H. Sherwood, Ph.D., President and Chief Executive Officer; Kevin W. Quinlan, Chief Financial Officer; Frank Luppino, Vice President of Operations; Connie Garrison, Vice President, Regulatory, Clinical, and Quality Systems
Ownership
Financials Mkt Cap :69


* numbers in thousands

Recent Results
 
Keywords
reconstruction, orthopedic

Comment | Printable Version | Nov. 01, 2008
If you work for Anika Therapeutics, Inc. and want to update this profile, click here

Description
Anika Therapeutics develops, manufactures and commercializes therapeutic devices to promote the protection and healing of bone, cartilage and soft tissue.
Products / Services
The company's products include ORTHOVISC and HYVISC, an HA product used in the treatment of joint diseases, such as osteoarthritis, and viscoelastic products used in eye surgery. They also produce ophthalmic products used surgical procedures, such as cataract extraction and intraocular lens implantation.
Technology / Differentiation
Their products are based on hyaluronic acid (HA), a natural chemical found throughout the body. HA enhances joint function and coats, protects, cushions and lubricates soft tissues.
Market / Customers
Anika Therapeutics has had a pioneering role in developing viscosupplementation to treat osteoarthritis. Osteoarthritis currently affects more than 21 million Americans over age 45. There is also a growing worldwide market for cosmetic tissue augmentation. The Company expects to commercially launch its first cosmetic filler product in 2006.
Competitors / Substitutes / Alternatives

Strategy
In July 2006 signed an exclusive worldwide development and commercialization agreement with Galderma Pharma S.A., a joint venture between Nestle and L'Oreal, for cosmetic tissue augmentation ("CTA") therapies. CTA therapies are used in patients for the correction of facial wrinkles, scar remediation, and lip augmentation.
Funding
Status


2008-11-22-572